Maze Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
MAZE$34.91+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $189,247 | $196,812 |
| Marketable securities, current | 152,670 | — |
| Prepaid expenses and other current assets | 7,800 | 4,859 |
| Total current assets | 349,717 | 201,671 |
| Property and equipment, net | 5,044 | 6,668 |
| Restricted cash | 1,088 | 1,088 |
| Marketable securities, non-current | 18,114 | — |
| Operating lease right-of-use asset | 20,116 | 23,250 |
| Other assets | 3,048 | 7,865 |
| Total assets | $397,127 | $240,542 |
| Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $1,794 | $1,939 |
| Accrued expenses and other current liabilities | 15,967 | 14,102 |
| Operating lease liabilities, current | 4,795 | 4,632 |
| Total current liabilities | 22,556 | 20,673 |
| Operating lease liabilities, net of current portion | 18,511 | 21,996 |
| Other liabilities, non-current | 1,094 | 969 |
| Total liabilities | 42,161 | 43,638 |
| Commitments and contingencies (Note 9) | ||
| Redeemable convertible preferred stock, $0.001 par value; no shares authorized, issued and outstanding as of December 31, 2025; 298,205,027 shares authorized and 297,205,041 shares issued and outstanding as of December 31, 2024; aggregate liquidation preference of $502,390 as of December 31, 2024 | — | 508,087 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.001 par value; 10,000,000 and no shares authorized as of December 31, 2025 and 2024, respectively; no shares issued and outstanding as of December 31, 2025 and 2024 | — | — |
| Common stock, $0.001 par value; 500,000,000 and 410,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 49,335,551 and 2,446,864 shares issued and outstanding as of December 31, 2025 and 2024, respectively; 10,372 shares subject to repurchase as of December 31, 2025 and 2024 | 49 | 2 |
| Additional paid-in-capital | 844,354 | 47,242 |
| Accumulated other comprehensive income | 110 | — |
| Accumulated deficit | (489,547) | (358,427) |
| Total stockholders’ equity (deficit) | 354,966 | (311,183) |
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | $397,127 | $240,542 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.